Media Alert: Interest in Peanut Allergy Market Heats up in the Wake of Aimmune/Nestlé Deal
September 01, 2020 15:55 ET
|
Intrommune Therapeutics
NEW YORK, Sept. 01, 2020 (GLOBE NEWSWIRE) -- The recent $2.6 billion acquisition of Aimmune by Nestlé Health Science has helped shed light on the global peanut allergy problem. In January 2020,...
Asthma and Allergy Foundation of America (AAFA) Appoints Melanie Carver Chief Mission Officer
August 06, 2020 08:53 ET
|
Asthma and Allergy Foundation of America
Washington, D.C., Aug. 06, 2020 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) is excited to announce Melanie Carver has been named Chief Mission Officer of the...
Allovate Therapeutics Extends Free Allerdent® Program
July 23, 2020 15:37 ET
|
Allovate, LLC
New York, July 23, 2020 (GLOBE NEWSWIRE) -- Allovate Therapeutics, a New York-based biotechnology company, announced today that it has extended its free Allerdent® program. Allerdent® is a...
Allovate Therapeutics Provides Free Allerdent® To Physicians
May 06, 2020 09:05 ET
|
Allovate, LLC
New York, May 06, 2020 (GLOBE NEWSWIRE) -- Allovate Therapeutics, a New York-based biotechnology company, announced today that it is making its allergy immunotherapy delivery platform available...
Survey Confirms Physician Interest in Peanut Allergy Immunotherapy
February 03, 2020 09:04 ET
|
Intrommune Therapeutics
New York, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly immunotherapy platform for the treatment of peanut and other...
The asthma & allergy friendly® Certification Program Featured Its Certified Products to the Homebuilding Industry’s Leaders and Experts From Across the Globe at the 2020 NAHB International Builders Show and Kitchen & Bath Industry Show
January 28, 2020 12:00 ET
|
Allergy Standards Limited
WASHINGTON, Jan. 28, 2020 (GLOBE NEWSWIRE) -- The asthma & allergy friendly® Certification Program, which is jointly run by Allergy Standards Limited (ASL) and the Asthma and Allergy Foundation...
Intrommune to Present at Biotech Showcase™ 2020
December 18, 2019 09:05 ET
|
Intrommune Therapeutics
New York, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics will attend and present at the upcoming Biotech Showcase™, which occurs during the annual J.P. Morgan Biotechnology...
Vystar Plans Dividend Spin Off of RxAir
October 16, 2019 08:00 ET
|
Vystar Corp
WORCESTER, Mass., Oct. 16, 2019 (GLOBE NEWSWIRE) -- Vystar Corp. (Vystar) (OTCQB Market: VYST) announced today that its Board of Directors has approved a plan to spin-off part of its RxAir air...
Intrommune Therapeutics Receives Support from Allergy & Asthma Network
September 13, 2019 09:05 ET
|
Intrommune Therapeutics
New York, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing the patient-friendly oral mucosal immunotherapy (OMIT) toothpaste platform for...
Newly Published Findings Validate Intrommune’s Approach to Treating Peanut and Other Food Allergies
September 05, 2019 15:20 ET
|
Intrommune Therapeutics
New York, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly immunotherapy platform for the treatment of peanut and...